Reports Q3 revenue $0 vs. $0 last year. “With the acceptance of our Biologics License Application resubmission for pz-cel, we are ramping up our commercial readiness efforts, especially with respect to onboarding potential pz-cel treatment sites and continuing discussions with payors,” said Vish Seshadri, Chief Executive Officer of Abeona.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces FDA acceptance of BLA resubmission of pz-cel
- Abeona Therapeutics Inc (ABEO) Q3 Earnings Cheat Sheet
- Abeona Therapeutics announces new employee inducement grants
- Abeona Therapeutics completes Pz-cel BLA resubmission to U.S. FDA
- Abeona Therapeutics announces employment inducement grants